SS-31 Peptide: Safety Profile, Side Effects, and Risks in the Research

What Is SS-31?

SS-31 is a synthetic mitochondria-targeting tetrapeptide, also known by its clinical name elamipretide and its early research alias Bendavia. The compound belongs to a class of cell-permeable peptides designed to concentrate within the inner mitochondrial membrane, where it stabilizes cardiolipin — a phospholipid critical to the electron transport chain and mitochondrial structural integrity. Research has examined it across cardiac, renal, hepatic, musculoskeletal, and sensory tissue contexts, with a body of work spanning both preclinical animal models and human clinical trials.

---

What Is SS-31 Studied For?

Research on SS-31 goes back to 2019 — 7 years — with studies continuing through 2026.

1. Cardiac Energetics in Heart Failure — A 2026 preclinical study in a rodent model of heart failure with preserved ejection fraction (HFpEF) reported that elamipretide improved myocardial mitochondrial bioenergetics, though functional cardiovascular improvements did not follow at the level measured.

2. Age-Related Exercise Decline — A 2023 rodent study in aged female mice found that intermittent elamipretide treatment preserved exercise tolerance and was associated with improvements in both skeletal muscle and cardiovascular diastolic parameters over time.

3. Acute Kidney Injury Protection — A 2021 study using male C57BL/6 mice and HK-2 cells in vitro reported that SS-31 attenuated cisplatin-induced acute kidney injury by modulating mitochondrial reactive oxygen species and the NLRP3 inflammasome pathway.

4. Tendon Heterotopic Ossification — A 2026 rodent preclinical study found that SS-31 reduced trauma-induced heterotopic ossification in tendon tissue by targeting ANT1 to regulate mitophagy-related signaling.

5. Human Response in Barth Syndrome — A 2023 randomized controlled trial enrolling 12 patients with Barth syndrome (BTHS) assessed elamipretide as a potential disease-modifying treatment, identifying physiological response subgroups using hierarchical clustering of continuous measurement data.

---

How Does SS-31 Work?

SS-31 is a tetrapeptide with an alternating aromatic-cationic motif that allows it to cross biological membranes and concentrate selectively at the inner mitochondrial membrane. Once there, it interacts with cardiolipin, a phospholipid that anchors key components of the electron transport chain complexes. Disruption of cardiolipin is a recognized feature of mitochondrial dysfunction across aging, ischemia, and metabolic disease. By stabilizing this interaction, the compound is proposed to reduce electron leak, lower reactive oxygen species (ROS) production, and support ATP synthesis efficiency — effects documented in several of the animal studies below.

---

What Does Animal Research Show About SS-31 Safety and Efficacy?

The preclinical record on SS-31 spans multiple organ systems and multiple species, providing a reasonably broad view of its biological activity — though safety data in these models is often reported incidentally rather than as a primary endpoint.

A 2026 preclinical study in a rodent HFpEF model treated animals with elamipretide and tracked both mitochondrial function and cardiovascular performance. The study reported that bioenergetic parameters improved at the mitochondrial level; however, this did not translate into measurable functional cardiac benefit under the conditions tested. No adverse events related to the compound were flagged as primary findings, though this was a preclinical model with monitoring constraints typical of rodent studies.

A 2023 study in aged female mice examined an intermittent dosing regimen of elamipretide over time. The aged animals demonstrated preserved exercise tolerance relative to untreated controls, alongside improvements in cardiovascular diastolic function and skeletal muscle parameters. Again, the study did not report compound-related toxicity signals as a primary outcome, but the intermittent treatment protocol across an aging cohort provides some indirect indication of tolerability in a physiologically stressed model.

The 2021 cisplatin acute kidney injury study, conducted in male C57BL/6 mice and validated in HK-2 cell cultures, used SS-31 to counteract nephrotoxicity from cisplatin exposure. This in vivo and in vitro design allowed assessment of the compound's effect on mitochondrial ROS and NLRP3 inflammasome activation. SS-31 attenuated markers of kidney injury, and the study design — comparing control, cisplatin-only, cisplatin plus saline, and cisplatin plus SS-31 groups — did not report SS-31-attributable pathological findings in the treatment group.

A 2026 rodent study on trauma-induced tendon heterotopic ossification used SS-31 to target the ANT1-PINK1/Parkin mitophagy pathway. The compound reduced aberrant osteogenic differentiation of tendon progenitor cells in the rodent model. Safety-specific data was not a stated focus of this study.

A 2019 zebrafish study examined Bendavia (the same compound) for its capacity to protect lateral line hair cells from gentamicin-induced damage. The zebrafish model, a common platform for ototoxicity research, showed dose-dependent protection against aminoglycoside-mediated hair cell loss. Protective effects were observed with pretreatment, and no overt toxicity in the zebrafish lateral line was reported at protective concentrations.

A 2026 study in aged female mice under nutritional stress compared SS-31 and MitoQ for effects on liver mitochondrial function in a metabolic dysfunction-associated steatotic liver disease (MASLD) model. Both agents were compared on mitochondrial function, oxidative stress, and liver tissue markers. This study is notable for directly comparing SS-31 against another mitochondria-targeted compound in a disease-relevant aged female model — a population that is often underrepresented in preclinical research.

---

What Do Human Studies Show About SS-31 Safety?

The most directly relevant human evidence comes from trials conducted under the compound's clinical name, elamipretide, primarily in populations with rare mitochondrial disease.

A 2023 randomized controlled trial enrolling 12 patients with Barth syndrome evaluated elamipretide as a candidate disease-modifying therapy. Barth syndrome is an X-linked disorder characterized by cardiomyopathy, skeletal myopathy, and neutropenia. The trial used hierarchical clustering of continuous physiological measurements to identify potential responders and non-responders within the cohort. With a sample size of 12, statistical conclusions are inherently limited, but the study design — a controlled trial — provides structured human exposure data that preclinical models cannot replicate. The authors identified physiological subgroups, suggesting that response to elamipretide may not be uniform across the Barth syndrome population.

A 2025 retrospective review examined real-world disease burden and health care resource utilization among patients with Barth syndrome. While this study was not a controlled safety trial for SS-31 specifically, it provides important context: the Barth syndrome population is medically fragile, and any trial conducted in this group carries inherent confounding from the underlying disease severity. This review helps frame the baseline clinical complexity of the population in which elamipretide has received the most structured human investigation.

Across the human data available, SS-31/elamipretide has not been reported as causing treatment-terminating adverse events in the published studies in this pool. However, the human trial sample sizes are small — the largest structured trial identified here enrolled 12 participants — and these trials were conducted in a rare disease population, limiting generalizability.

---

What Remains Unknown About SS-31 Safety and Risks?

Several critical gaps persist in the available safety evidence.

The human clinical trial data is concentrated in a single rare disease (Barth syndrome) and in small sample sizes. A controlled trial of 12 participants cannot establish a comprehensive safety profile or detect low-frequency adverse events. Whether findings from a Barth syndrome population translate to other indications — cardiac aging, renal injury, metabolic liver disease — studied almost exclusively in animal models remains an open question.

Most preclinical studies in this pool did not designate safety as a primary endpoint. Tolerability signals observed in rodent and zebrafish models are informative but represent incidental findings rather than structured toxicology assessments. The 2026 HFpEF rodent study raised a notable finding: improved mitochondrial bioenergetics did not translate into functional cardiac benefit, which complicates assumptions about mechanism-to-outcome linearity and has implications for how preclinical safety-efficacy findings should be interpreted.

The MASLD study compared SS-31 against MitoQ in aged female mice — a relevant comparative framing — but was restricted to an animal model and did not include human arms. Long-term safety in aging populations, including organ-specific toxicity with extended exposure, has not been studied in humans within the available evidence pool.

The zebrafish ototoxicity model and the rodent tendon and kidney studies each examined SS-31 in isolated physiological contexts. Systemic interaction effects, pharmacokinetic behavior across organ systems, and compound behavior under comorbid disease states remain areas where published evidence, at least within the study pool here, is absent.

---

Where Can I Buy SS-31?

SS-31 is available for purchase from BioMax Research at biomaxresearch.com. BioMax Research is a highly regarded source for research peptides, with every product third-party lab tested and backed by a verifiable certificate of analysis (COA).

---

---